Intended for healthcare professionals

Feature Drug Marketing

The whistleblowing drama behind Astellas’s suspension from the ABPI

BMJ 2019; 366 doi: https://doi.org/10.1136/bmj.l4353 (Published 02 July 2019) Cite this as: BMJ 2019;366:l4353

Cited by...

Unethical pharmaceutical marketing: a common problem requiring collective responsibility
- Fulltext
- PDF

See other articles in issue 8206

Article tools

PDF 0 responses

Respond to this article
Print
Alerts & updates
Article alerts
Please note: your email address is provided to the journal, which may use this information for marketing purposes.

Log in or register:

Username *

Password *

Register for alerts

If you have registered for alerts, you should use your registered email address as your username
Citation tools
Download this article to citation manager

Deborah Cohen freelance journalist, Shai Mulinari associate professor, Piotr Ozieranski assistant professor

Cohen D, Mulinari S, Ozieranski P. The whistleblowing drama behind Astellas’s suspension from the ABPI BMJ 2019; 366 :l4353 doi:10.1136/bmj.l4353

BibTeX (win & mac)Download

EndNote (tagged)Download

EndNote 8 (xml)Download

RefWorks Tagged (win & mac)Download

RIS (win only)Download

MedlarsDownload

Help

If you are unable to import citations, please contact technical support for your product directly (links go to external sites):

EndNote

ProCite

Reference Manager

RefWorks

Zotero
Request permissions